Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Surrozen, Inc. filings on SEC EDGAR ↗
Surrozen, Inc. entered into an underwriting agreement for a public offering of 1,894,540 shares of common stock at a price of $31.67 per share. The company expects to receive gross proceeds of approximately $60 million from the offering, which is scheduled to close on November 16, 2026.
Value
$60M
Counterparty
Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co.
Surrozen completed the second and final tranche of a private placement, raising approximately $95.1 million in gross proceeds. The closing was triggered by the achievement of a milestone involving FDA clearance of the IND application for SZN-8141. The funding is expected to provide a cash runway into 2029 to advance the company's ophthalmology pipeline through clinical milestones.
Value
$95.1M
“The completion of this financing marks an important milestone for Surrozen, significantly strengthening our balance sheet and providing the resources to advance our ophthalmology pipeline through multiple important clinical milestones.”
Craig Parker, President and Chief Executive Officer
“With expected cash runway into 2029, we are well positioned to advance SZN-8141 into the DUET Phase 1b/2a study and initiate clinical development of SZN-8143, while maintaining a disciplined approach to capital allocation.”
Craig Parker, President and Chief Executive Officer
Surrozen announced that the FDA clearance of its IND application for SZN-8141 triggered a second closing milestone under a previously announced private placement. This second tranche is expected to provide approximately $95.1 million in gross proceeds on or about October 20, 2026, to support clinical development and operations.